For all the attention usually paid to biotechnology stocks and exchange-traded funds, arguably, it feels as though the November rally experienced by this volatile sector was often overlooked. Overlooked or not, that does not change the fact that during November, three of the top 10 non-leveraged ETFs in terms of percentage gain were biotech funds.
Non-Leveraged Biotech ETF Wins
That trio includes the SPDR S&P Biotech (ETF) (NYSE: XBI). XBI, the third-largest biotechnology ETF by assets, climbed 8.5 percent last month, a performance topped by just six other ETFs. XBI equally weights its 103 holdings, and the results have been stellar.
Over the past three years, XBI has surged 153.2 percent, topping the next closest biotech ETF by 300 basis points. As has been proven with other equal-weight ETFs, there are benefits to the methodology.
/www.benzinga.com/general/biotech/15/12/6010460/another-visit-with-a-leveraged-biotech-etf alt=Another Visit With A Leveraged Biotech ETF>Full story available on Benzinga.com
More...